Clinical Study to Evaluate Tolerability and Safety of ARK-E021 Foam and to Monitor Clinical Effect in Acne Vulgaris Patients

NCT ID: NCT01494285

Last Updated: 2013-12-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 157 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-06-30
• Study Completion Date: 2013-10-31

Brief Summary

This is a multicenter, randomized, double-blind, placebo-controlled, 3-arm, parallel-group, ambulatory safety and efficacy study of ARK-E021 topical foam of 5% and 10% in subjects with mild to moderate acne vulgaris.

Detailed Description

This is a phase I/II prospective, multicenter, randomized, double blind, placebo controlled, parallel group, dose range finding clinical study to evaluate the safety, tolerability and preliminary efficacy of ARK-E021 foam for treatment of acne vulgaris.

It is anticipated that the study will be conducted at the listed Medical Centers as well as out-patient clinics at the community.

Approximately 144 male and female subjects with mild to moderate facial acne vulgaris will be enrolled in this study. Following satisfaction of the entry criteria and screening procedures, subjects will be randomized to either 5% or 10% topical foam (ARK-E021) or placebo foam. Subjects will apply the study medication once daily on the face at bedtime for 12 weeks followed by a post-treatment follow up visit 4 weeks after end of treatment. The first dose will be applied in the presence of the study investigator or his assignee. Subsequent applications will be made by the patient.

Safety will be monitored throughout the study duration. Efficacy will be assessed by facial lesion counts and by the investigator global evaluation of acne severity at baseline and at weeks 3, 6, 9, 12 and 16.

Conditions

Acne Vulgaris

Keywords

Acne Vulgaris; Topical; Foam

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

ARK-E021 5% foam

Group Type: EXPERIMENTAL

ARK-E021 5%

Intervention Type: DRUG

Topically applied once daily at bedtime

ARK-E021 10% foam

Group Type: EXPERIMENTAL

ARK-E021 10%

Intervention Type: DRUG

Topically applied once daily at bedtime

Placebo foam

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Topically applied once daily at bedtime

Interventions

ARK-E021 5%

Topically applied once daily at bedtime

Intervention Type: DRUG

ARK-E021 10%

Topically applied once daily at bedtime

Intervention Type: DRUG

Placebo

Topically applied once daily at bedtime

Intervention Type: DRUG

Other Intervention Names

Not yet marketed; Not yet marketed; Not marketed

Eligibility Criteria

Inclusion Criteria

• Patient is male or female between the ages of 12 to 40.
• A clinical diagnosis of acne vulgaris with facial involvement.
• Minimum of 15 inflammatory lesions on the face (papules and/ or pustules)but not more than 40.
• Existence of non-inflammatory lesions on the face (opened and/or closed comedones).
• A score of ≥2 (moderate) on the investigator's global assessment scale.
• Use of non oral contraceptives in female of childbearing potential during the study.
• No known medical conditions that, in the Investigator's opinion could interfere with study participation.
• Patient is willing and able to comply with all the requirement of the study protocol.
• Patient is willing and able to give written informed consent prior to participation in the study.

Exclusion Criteria

• Acne conglobata, acne fulminans, secondary acne (chloracne, drug induced acne), or severe acne requiring systemic treatment.
• One or more active nodule/cyst acne on the face (inactive lesions allowed).
• Excessive facial hair (e.g. beards, sideburns, moustaches, etc.) that would interfere with diagnosis or assessment of acne vulgaris.
• Participation in another investigational drug trial within 30 days prior to study entry.
• Concomitant medication:

• Use of systemic steroids, systemic antibiotics, systemic treatment for acne vulgaris, systemic anti-inflammatory agents within 4 weeks prior to baseline or during the study.
• Use of topical steroids, topical antibiotics, topical treatment for acne vulgaris, topical anti-inflammatory agents within 2 weeks prior to baseline or during the study.
• Treatment for acne with isotretinoin or isotretinoin derivatives within 12 months prior to study entry.

• Minimum Eligible Age: 12 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Vyne Therapeutics Inc.

INDUSTRY

Sponsor Role: collaborator

M. Arkin 1999 Ltd.

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

HaEmek Medical Center

Afula, , Israel

Meir Medical Center

Kfar Saba, , Israel

Souraski Medical Center

Tel Aviv, , Israel

Countries

Israel

Other Identifiers

MA1001

Identifier Type: -

Identifier Source: org_study_id